PURPOSE: The first United Kingdom Children's Cancer Study Group (UKCCSG) Wilms' Tumor Trial (UKW1) applied treatment regimens stratified by stage and histology in accordance with National Wilms' Tumor Study (NWTS) criteria, seeking to reduce treatment of low-stage, favorable-histology (FH) tumors without impairing survival and to improve prognosis of stage III and IV (FH) and unfavorable-histology (UH) tumors with more intensive chemotherapy. PATIENTS AND METHODS: Three hundred eighty-four consecutively diagnosed patients with Wilms' tumor were recruited from the 20 UKCCSG centers and Oslo, Norway, between January 1980 and June 1986. The regimen for stage I patients was vincristine (Vcr) only, while stage II patients received Vcr and dactinomycin (Act-D). Stage III patients received three-drug therapy and stage IV and UH patients four-drug regimens. Act-D was given as pulsed doses of 1.5 mg/m2 every 3 or every 6 weeks. No lung irradiation was used in stage IV patients. No randomized comparisons were attempted. End points were survival and event-free survival (EFS). RESULTS:Survival at 6 years in FH patients was 96% for stage I, 93% for stage II, 83% for stage III, 65% for stage IV, and 50% for UH patients of all stages. CONCLUSION: Vcr alone is as effective for stage I FH tumors as the two-drug regimen used in the NWTS and International Society of Pediatric Oncology (SIOP) studies. Fractionation of Act-D is unnecessary. The poorer results for stage IV FH and UH patients compared with the NWTS may be due to treatment differences, such as the use of lung irradiation for stage IV FH patients in NWTS3, and/or to case selection bias.
RCT Entities:
PURPOSE: The first United Kingdom Children's Cancer Study Group (UKCCSG) Wilms' Tumor Trial (UKW1) applied treatment regimens stratified by stage and histology in accordance with National Wilms' Tumor Study (NWTS) criteria, seeking to reduce treatment of low-stage, favorable-histology (FH) tumors without impairing survival and to improve prognosis of stage III and IV (FH) and unfavorable-histology (UH) tumors with more intensive chemotherapy. PATIENTS AND METHODS: Three hundred eighty-four consecutively diagnosed patients with Wilms' tumor were recruited from the 20 UKCCSG centers and Oslo, Norway, between January 1980 and June 1986. The regimen for stage I patients was vincristine (Vcr) only, while stage II patients received Vcr and dactinomycin (Act-D). Stage III patients received three-drug therapy and stage IV and UH patients four-drug regimens. Act-D was given as pulsed doses of 1.5 mg/m2 every 3 or every 6 weeks. No lung irradiation was used in stage IV patients. No randomized comparisons were attempted. End points were survival and event-free survival (EFS). RESULTS: Survival at 6 years in FH patients was 96% for stage I, 93% for stage II, 83% for stage III, 65% for stage IV, and 50% for UH patients of all stages. CONCLUSION: Vcr alone is as effective for stage I FH tumors as the two-drug regimen used in the NWTS and International Society of Pediatric Oncology (SIOP) studies. Fractionation of Act-D is unnecessary. The poorer results for stage IV FH and UH patients compared with the NWTS may be due to treatment differences, such as the use of lung irradiation for stage IV FH patients in NWTS3, and/or to case selection bias.
Authors: Heidi Russell; J Michael Swint; Lincy Lal; Jane Meza; David Walterhouse; Douglas S Hawkins; M Fatih Okcu Journal: Pediatr Blood Cancer Date: 2014-01-22 Impact factor: 3.167
Authors: John A Kalapurakal; Mahesh Gopalakrishnan; David O Walterhouse; Cynthia K Rigsby; Alfred Rademaker; Irene Helenowski; Sandy Kessel; Karen Morano; Fran Laurie; Ken Ulin; Natia Esiashvili; Howard Katzenstein; Karen Marcus; David S Followill; Suzanne L Wolden; Anita Mahajan; Thomas J Fitzgerald Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-29 Impact factor: 7.038
Authors: Saskia L Gooskens; Norbert Graf; Rhoikos Furtwängler; Filippo Spreafico; Christophe Bergeron; Gema L Ramírez-Villar; Jan Godzinski; Christian Rübe; Geert O Janssens; Gordan M Vujanic; Ivo Leuschner; Aurore Coulomb-L'Hermine; Anne M Smets; Beatriz de Camargo; Sara Stoneham; Harm van Tinteren; Kathy Pritchard-Jones; Marry M van den Heuvel-Eibrink Journal: Nat Rev Urol Date: 2018-02-27 Impact factor: 14.432
Authors: Richard H Scott; Anne Murray; Linda Baskcomb; Clare Turnbull; Chey Loveday; Reem Al-Saadi; Richard Williams; Fin Breatnach; Mary Gerrard; Juliet Hale; Janice Kohler; Pablo Lapunzina; Gill A Levitt; Sue Picton; Barry Pizer; Milind D Ronghe; Heidi Traunecker; Denise Williams; Anna Kelsey; Gordan M Vujanic; Neil J Sebire; Paul Grundy; Charles A Stiller; Kathy Pritchard-Jones; Jenny Douglas; Nazneen Rahman Journal: Oncotarget Date: 2012-03
Authors: Hemant B Tongaonkar; Sajid S Qureshi; Purna A Kurkure; Mary-Ann A Muckaden; Brijesh Arora; Thyavihalli B Yuvaraja Journal: Indian J Urol Date: 2007-10